8.3
公开持仓披露/交易披露
由持有相关证券 1% 或以上权益的个人进行
收购守则第 8.3 条（“守则”）
1. 关键信息
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露者全名：</td>
<td>Rathbones Group Plc</td>
</tr>
<tr>
<td>(b) 权益和空头头寸的所有者或控制者（如与 1(a) 不同）： 提名或公司名称不足以说明。对于信托，必须列出受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>(c) 与本表格相关的要约方/被要约方名称： 每个要约方/被要约方使用单独的表格</td>
<td>Advanced Medical Solutions Group plc</td>
</tr>
<tr>
<td>(d) 如果是与要约方/被要约方相关的豁免基金经理，请说明并指定要约方/被要约方的身份：</td>
<td></td>
</tr>
<tr>
<td>(e) 持仓日期/交易日期： 对于公开持仓披露，请说明披露前的最新可行日期</td>
<td>17/04/2026</td>
</tr>
<tr>
<td>(f) 除了上述 1(c) 中的公司外，披露者是否还在披露任何其他要约方的相关信息？ 如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>否</td>
</tr>
</tbody>
</table>
2. 披露者的持仓
如果在 1(c) 中提到的要约方或被要约方的多个类别相关证券中有持仓或认购权需要披露，请为每个额外类别的相关证券复制表格 2(a) 或 (b)（视情况而定）。
(a) 与披露相关的要约方或被要约方的相关证券的权益和空头头寸（如有）
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别：</td>
<td>5 便士普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>权益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券：</td>
<td>14,494,709</td>
<td>6.59%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 现金结算衍生品：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 股票结算衍生品（包括期权）和购买/出售协议：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计：</td>
<td>14,494,709</td>
<td>6.59%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
所有权益和所有空头头寸应予以披露。
任何开放的股票结算衍生品持仓（包括交易期权）或购买或出售相关证券的协议应在补充表格 8（开放持仓）中提供详细信息。
(b) 认购新证券的权利（包括董事和其他员工期权）
<ul>
<li>与认购权相关的相关证券类别：</li>
<li>详细信息，包括相关权利的性质和相关百分比：</li>
</ul>
3. 披露者的交易（如有）
如果在 1(c) 中提到的要约方或被要约方的多个类别相关证券中有交易，请为每个额外类别的相关证券复制表格 3(a)、(b)、(c) 或 (d)（视情况而定）。
所有价格和其他货币金额的货币单位应予以说明。
(a) 购买和销售
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>5 便士普通股</td>
</tr>
<tr>
<td>购买/销售</td>
<td></td>
</tr>
<tr>
<td>证券数量</td>
<td></td>
</tr>
<tr>
<td>单价</td>
<td></td>
</tr>
</tbody>
</table>
(b) 现金结算衍生品交易
<ul>
<li>相关证券类别</li>
<li>产品描述 例如：CFD</li>
<li>交易性质 例如：开立/平仓多头/空头头寸，增加/减少多头/空头头寸</li>
<li>参考证券数量</li>
<li>单价</li>
</ul>
(c) 股票结算衍生品交易（包括期权）
(i) 写入、出售、购买或变更
<ul>
<li>相关证券类别</li>
<li>产品描述 例如：看涨期权</li>
<li>写入、购买、出售、变更等</li>
<li>与期权相关的证券数量</li>
<li>每单位行使价格</li>
<li>类型 例如：美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付的期权费用</li>
</ul>
(ii) 行使
<ul>
<li>相关证券类别</li>
<li>产品描述 例如：看涨期权</li>
<li>行使/已行使</li>
<li>证券数量</li>
<li>每单位行使价格</li>
</ul>
(d) 其他交易（包括认购新证券）
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>5 便士普通股</td>
</tr>
<tr>
<td>交易性质 例如：认购、转换</td>
<td></td>
</tr>
<tr>
<td>详细信息</td>
<td></td>
</tr>
<tr>
<td>单价（如适用）</td>
<td></td>
</tr>
</tbody>
</table>
4. 其他信息
(a) 赔偿和其他交易安排
<ul>
<li>披露者与要约方或与要约方一致行动的任何人之间的任何赔偿或期权安排，或任何与相关证券有关的协议或理解（正式或非正式），可能会诱使进行或避免进行交易的详细信息： 不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
(b) 与期权或衍生品相关的协议、安排或理解
<ul>
<li>披露者与任何其他人之间的任何协议、安排或理解（正式或非正式）的详细信息，涉及： (i) 任何期权下相关证券的投票权；或 (ii) 任何衍生品所参考的相关证券的投票权或未来的收购或处置： 如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
(c) 附件
<ul>
<li>是否附有补充表格 8（开放持仓）？</li>
<li>否</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>20/04/2026</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Callum Ridley – 合规部门</td>
</tr>
<tr>
<td>联系电话：</td>
<td>0151 243 7037</td>
</tr>
</tbody>
</table>
根据守则第 8 条的公开披露必须向监管信息服务进行。
委员会的市场监督单位可就《守则》的披露要求提供咨询，联系电话为 +44 (0) 20 7638 0129.
《守则》可在委员会的网站上查看。

Rathbones Group Plc 披露了在 Advanced Medical Solutions Group plc 的开仓头寸，持有 14,494,709 股，代表该公司相关证券的 6.59%。该披露是根据收购守则第 8.3 条进行的，未涉及其他参与方。该头寸截至 2026 年 4 月 17 日持有，披露日期为 2026 年 4 月 20 日。未报告任何额外协议或安排

8.3
<div class="lb-trans">8.3
</div>PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
<div class="lb-trans">公开持仓披露/交易披露
</div>A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
<div class="lb-trans">由持有相关证券 1% 或以上权益的个人进行
</div>Rule 8.3 of the Takeover Code (the “Code”)
<div class="lb-trans">收购守则第 8.3 条（“守则”）
</div>1. KEY INFORMATION
<div class="lb-trans">1. 关键信息
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Full name of discloser:</td>
<td>Rathbones Group Plc</td>
</tr>
<tr>
<td>(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</td>
<td></td>
</tr>
<tr>
<td>(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree</td>
<td>Advanced Medical Solutions Group plc</td>
</tr>
<tr>
<td>(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:</td>
<td></td>
</tr>
<tr>
<td>(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure</td>
<td>17/04/2026</td>
</tr>
<tr>
<td>(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”</td>
<td>No</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露者全名：</td>
<td>Rathbones Group Plc</td>
</tr>
<tr>
<td>(b) 权益和空头头寸的所有者或控制者（如与 1(a) 不同）： 提名或公司名称不足以说明。对于信托，必须列出受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>(c) 与本表格相关的要约方/被要约方名称： 每个要约方/被要约方使用单独的表格</td>
<td>Advanced Medical Solutions Group plc</td>
</tr>
<tr>
<td>(d) 如果是与要约方/被要约方相关的豁免基金经理，请说明并指定要约方/被要约方的身份：</td>
<td></td>
</tr>
<tr>
<td>(e) 持仓日期/交易日期： 对于公开持仓披露，请说明披露前的最新可行日期</td>
<td>17/04/2026</td>
</tr>
<tr>
<td>(f) 除了上述 1(c) 中的公司外，披露者是否还在披露任何其他要约方的相关信息？ 如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>否</td>
</tr>
</tbody>
</table>
</div>2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
<div class="lb-trans">2. 披露者的持仓
</div>If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
<div class="lb-trans">如果在 1(c) 中提到的要约方或被要约方的多个类别相关证券中有持仓或认购权需要披露，请为每个额外类别的相关证券复制表格 2(a) 或 (b)（视情况而定）。
</div>(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
<div class="lb-trans">(a) 与披露相关的要约方或被要约方的相关证券的权益和空头头寸（如有）
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security:</td>
<td>5p Ordinary Shares</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interests</td>
<td>Short positions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number</td>
<td>%</td>
<td>Number</td>
<td>%</td>
</tr>
<tr>
<td>(1) Relevant securities owned and/or controlled:</td>
<td>14,494,709</td>
<td>6.59%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) Cash-settled derivatives:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) Stock-settled derivatives (including options) and agreements to purchase/sell:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL:</td>
<td>14,494,709</td>
<td>6.59%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别：</td>
<td>5 便士普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>权益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券：</td>
<td>14,494,709</td>
<td>6.59%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 现金结算衍生品：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 股票结算衍生品（包括期权）和购买/出售协议：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计：</td>
<td>14,494,709</td>
<td>6.59%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div>All interests and all short positions should be disclosed.
<div class="lb-trans">所有权益和所有空头头寸应予以披露。
</div>Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
<div class="lb-trans">任何开放的股票结算衍生品持仓（包括交易期权）或购买或出售相关证券的协议应在补充表格 8（开放持仓）中提供详细信息。
</div>(b) Rights to subscribe for new securities (including directors’ and other employee options)
<div class="lb-trans">(b) 认购新证券的权利（包括董事和其他员工期权）
</div><ul>
<li>Class of relevant security in relation to which subscription right exists:</li>
<li>Details, including nature of the rights concerned and relevant percentages:</li>
</ul>
<div class="lb-trans"><ul>
<li>与认购权相关的相关证券类别：</li>
<li>详细信息，包括相关权利的性质和相关百分比：</li>
</ul>
</div>3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
<div class="lb-trans">3. 披露者的交易（如有）
</div>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
<div class="lb-trans">如果在 1(c) 中提到的要约方或被要约方的多个类别相关证券中有交易，请为每个额外类别的相关证券复制表格 3(a)、(b)、(c) 或 (d)（视情况而定）。
</div>The currency of all prices and other monetary amounts should be stated.
<div class="lb-trans">所有价格和其他货币金额的货币单位应予以说明。
</div>(a) Purchases and sales
<div class="lb-trans">(a) 购买和销售
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security</td>
<td>5p Ordinary Shares</td>
</tr>
<tr>
<td>Purchase/sale</td>
<td></td>
</tr>
<tr>
<td>Number of securities</td>
<td></td>
</tr>
<tr>
<td>Price per unit</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>5 便士普通股</td>
</tr>
<tr>
<td>购买/销售</td>
<td></td>
</tr>
<tr>
<td>证券数量</td>
<td></td>
</tr>
<tr>
<td>单价</td>
<td></td>
</tr>
</tbody>
</table>
</div>(b) Cash-settled derivative transactions
<div class="lb-trans">(b) 现金结算衍生品交易
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. CFD</li>
<li>Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position</li>
<li>Number of reference securities</li>
<li>Price per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述 例如：CFD</li>
<li>交易性质 例如：开立/平仓多头/空头头寸，增加/减少多头/空头头寸</li>
<li>参考证券数量</li>
<li>单价</li>
</ul>
</div>(c) Stock-settled derivative transactions (including options)
<div class="lb-trans">(c) 股票结算衍生品交易（包括期权）
</div>(i) Writing, selling, purchasing or varying
<div class="lb-trans">(i) 写入、出售、购买或变更
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Writing, purchasing, selling, varying etc.</li>
<li>Number of securities to which option relates</li>
<li>Exercise price per unit</li>
<li>Type e.g. American, European etc.</li>
<li>Expiry date</li>
<li>Option money paid/ received per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述 例如：看涨期权</li>
<li>写入、购买、出售、变更等</li>
<li>与期权相关的证券数量</li>
<li>每单位行使价格</li>
<li>类型 例如：美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付的期权费用</li>
</ul>
</div>(ii) Exercise
<div class="lb-trans">(ii) 行使
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Exercising/ exercised against</li>
<li>Number of securities</li>
<li>Exercise price per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述 例如：看涨期权</li>
<li>行使/已行使</li>
<li>证券数量</li>
<li>每单位行使价格</li>
</ul>
</div>(d) Other dealings (including subscribing for new securities)
<div class="lb-trans">(d) 其他交易（包括认购新证券）
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security</td>
<td>5p Ordinary Shares</td>
</tr>
<tr>
<td>Nature of dealing e.g. subscription, conversion</td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>Price per unit (if applicable)</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>5 便士普通股</td>
</tr>
<tr>
<td>交易性质 例如：认购、转换</td>
<td></td>
</tr>
<tr>
<td>详细信息</td>
<td></td>
</tr>
<tr>
<td>单价（如适用）</td>
<td></td>
</tr>
</tbody>
</table>
</div>4. OTHER INFORMATION
<div class="lb-trans">4. 其他信息
</div>(a) Indemnity and other dealing arrangements
<div class="lb-trans">(a) 赔偿和其他交易安排
</div><ul>
<li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”</li>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>披露者与要约方或与要约方一致行动的任何人之间的任何赔偿或期权安排，或任何与相关证券有关的协议或理解（正式或非正式），可能会诱使进行或避免进行交易的详细信息： 不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
</div>(b) Agreements, arrangements or understandings relating to options or derivatives
<div class="lb-trans">(b) 与期权或衍生品相关的协议、安排或理解
</div><ul>
<li>Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”</li>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>披露者与任何其他人之间的任何协议、安排或理解（正式或非正式）的详细信息，涉及： (i) 任何期权下相关证券的投票权；或 (ii) 任何衍生品所参考的相关证券的投票权或未来的收购或处置： 如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
</div>(c) Attachments
<div class="lb-trans">(c) 附件
</div><ul>
<li>Is a Supplemental Form 8 (Open Positions) attached?</li>
<li>No</li>
</ul>
<div class="lb-trans"><ul>
<li>是否附有补充表格 8（开放持仓）？</li>
<li>否</li>
</ul>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure:</td>
<td>20/04/2026</td>
</tr>
<tr>
<td>Contact name:</td>
<td>Callum Ridley – Compliance Department</td>
</tr>
<tr>
<td>Telephone number:</td>
<td>0151 243 7037</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>20/04/2026</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Callum Ridley – 合规部门</td>
</tr>
<tr>
<td>联系电话：</td>
<td>0151 243 7037</td>
</tr>
</tbody>
</table>
</div>Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
<div class="lb-trans">根据守则第 8 条的公开披露必须向监管信息服务进行。
</div>The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0) 20 7638 0129.
<div class="lb-trans">委员会的市场监督单位可就《守则》的披露要求提供咨询，联系电话为 +44 (0) 20 7638 0129.
</div>The Code can be viewed on the Panel’s website at.
<div class="lb-trans">《守则》可在委员会的网站上查看。
</div>

表格 8.3 - Advanced Medical Solutions Group